Abstract
20526 Background: Bisphosphonate (BP) therapy is indicated in the treatment of pts. with symptomatic bony disease secondary to myeloma, solid tumors and in the treatment of osteoporosis. We have previously reported our experience with BP related osteonecrosis of the jaw (ONJ) (J Oral Maxillofac Surg 2004;62:527–34). The reported incidence of this entity in patients receiving IV BP’s is approx. 1–10%. The purpose of our current report is to update our experience and report the clinical outcome of the osteonecrotic lesion, with particular emphasis to clinical stage and after following stage specific management guidelines that we have previously published (Hematology 2006; 356–360). Methods: We performed a retrospective analysis of pts. records that were diagnosed with ONJ at our institution. IRB approval was obtained for this study. Information regarding age, gender, indication for BP treatment, type of BP used, stage of ONJ at time of presentation, outcome of ONJ with appropriate therapy were recorded. Res...